Business Wire

XPENG To Attend IAA Mobility 2023 as EU Deliveries Begin

30.8.2023 13:45:00 EEST | Business Wire | Press release

Share

XPeng Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the beginning of P7 deliveries in four key European markets and its participation in IAA Mobility 2023, Munich, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830333578/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

European P7 Delivery

Outstanding Smart EVs for Europe

XPENG G9 and P7 were launched in February this year, with excitement around the brand and positive feedback continuing to build up with deliveries beginning.

In June, XPENG G9 broke the charging record at the two-day NAF (Norwegian Automobile Federation) and Motor EV Summer test, also known as El-Prix 2023, reaching a peak charging power of 319 kW. This also represented the test's highest average charging power at 212 kW, allowing drivers to charge up to 100 km of range in just five minutes. G9 and P7 occupied the top two spots in the range test, which measures the real-world deviation rate compared to the stated WLTP range; there was an increase of 13% and 10% for G9(4WD) and P7(4WD), respectively.

As a spacious sports sedan, XPENG P7's cabin provides exceptional comfort, which is surrounded by a sleek exterior epitomizing XPENG's Dynamic Aesthetics design language. Deliveries of P7 recently commenced, with the first batches of vehicles having arrived at XPENG's delivery centers in Lørenskog, Norway; Järfälla, Sweden; Hillerød, Denmark; and Badhoevedorp, The Netherlands.

"We’re delighted that customers who placed orders at the very beginning can finally drive P7 on Europe’s roads,” said Eric Xu, VP of International Markets XPENG. “The feedback has been positive so far, and with our rapidly growing network, we’re very optimistic about our future on the continent.”

Drive With Confidence

As part of the company's dedication to delivering superior customer experiences, XPENG is offering a comprehensive service agreement, which includes an eight-year warranty for the vehicle's battery, as well as a seven-year/160,000 km extended warranty for all orders placed in 2023.

Deliveries of G9 will begin in the coming months as XPENG's network of authorized agencies and partners expands, which will optimize sales, delivery, and servicing processes to create a seamless customer journey.

Learn More About XPENG P7 for Europe

https://www.heyxpeng.com/nl/p7

https://www.heyxpeng.com/dk/p7

https://www.heyxpeng.com/no/p7

https://www.heyxpeng.com/se/p7

XPENG at IAA Mobility 2023

As a technology pioneer in the mobility industry, XPENG will participate in the world's largest mobility event this year, IAA Mobility, on September 4–10, 2023 in Munich. XPENG's agenda is as follows:

  • Pre-IAA XPENG Press Conference
    • H4 Hotel Munich Messe
    • Monday, September 4, 11 am–12 pm
  • IAA Summit Panel: Unleashing the Integrated Smart Ecosystem
    • Blue Stage
    • A discussion on how intelligent and autonomous vehicles are transforming the industry and our overall mobility experience
    • Featuring Co-President and Vice Chairman Brian Gu
    • Tuesday, September 5, 3 pm–3:45 pm
  • Open Space Activation with Product Displays
    • Konigsplatz, Stand KP155
    • Tuesday, September 5 – Sunday, September 10, 10 am–8 pm
  • P7 and G9 Test Drives at Blue Lane*
    • Near Hall C3, Munich Messe
      • Monday, September 4, 8 am–6 pm
      • Tuesday, September 5 – Friday, September 8, 9 am–6 pm
    • Near Konigsplatz
      • Tuesday, September 5 – Saturday, September 9, 10 am–8 pm
      • Sunday, September 10, 10 am–5 pm

*Subject to pre-booking

Follow XPENG at IAA Mobility 2023

Instagram

LinkedIn

Twitter

Facebook

About XPENG

XPENG is a global smart electric vehicle company founded in 2014 in Guangzhou, China, developing clean, intuitive, and creative mobility solutions. With industry-leading R&D facilities, XPENG is bringing vehicles with superior safety, electric efficiency, and on-road performance to markets across the globe. The company is constantly working to advance its core technology offering, including autonomous driving capabilities, SEPA 2.0, and captivating in-car infotainment systems. XPENG has headquarters in Guangzhou and Amsterdam, with additional offices in Beijing, Shanghai, and Silicon Valley.

Visit heyxpeng.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries: pr@xiaopeng.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye